跳至主要内容
临床试验/NCT06479057
NCT06479057招募中不适用

Integrating PROACTive Care Pathways to Empower and Support Cancer Patients (PROACT)

Gustave Roussy, Cancer Campus, Grand Paris1 个研究点 分布在 1 个国家目标入组 700 人开始时间: 2024年1月11日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
700
试验地点
1
主要终点
Patient distress

研究概览

简要总结

PROACT is a prospective master protocol for a cohort study focused on evaluating the implementation of integrated proactive pathways of supportive care.

This is an observational cohort study in the context of a quality-of-care initiative.

It will be evaluated by its impact on patient's distress measured by the NCCN's Distress thermometer at 12 weeks after entering the pathway.

详细描述

The primary study endpoint of PROACT is patient distress and supportive care needs (NCCN Distress Thermometer and NCCN Problem list) over a 12-week period after the supportive care needs assessment and referrals in the context of a PROACT pathway.

Secondary study endpoints include:

  1. To evaluate the Reach of each pathway through the number of patients who participated in supportive care needs' assessment and in each supportive care intervention (administrative review of attendance log)
  2. To evaluate the diversity of patients included in each pathways through evaluation of sociodemographic and economic profile (Socioeconomic and demographic self-reported questionnaire)
  3. To evaluate the impact of each pathway and each supportive care intervention on patient's overall health status (EQ-E5-EL)
  4. To evaluate the impact of each pathway and each supportive care intervention on patient's quality of life (EORTC QLQ C30)
  5. To evaluate the impact of each pathway and each supportive care intervention on symptom burden (MDASI)
  6. To evaluate the impact of each pathway and each supportive care intervention on anxiety (HADS)
  7. To evaluate the impact of each pathway and each supportive care intervention on Insomnia levels (ISI)
  8. To evaluate the impact of each pathway and each supportive care intervention on sexual health (EORTC SHQ-C22)
  9. To evaluate the Physician's Adoption of each pathway through the proportion of physicians referring patients to the pathways (referral log)
  10. To evaluate patient's adoption through the proportion of patients adhering to supportive care interventions as intended (attendance log)
  11. To evaluate patient experience and satisfaction with the pathways (PACIC and adhoc satisfaction questionnaires.
  12. To evaluate implementation in through a qualitative analyses of experience, implementation barriers and facilitators (focus groups with patients and providers)
  13. To plan for Maintenance of the pathway through a cost effectiveness analysis.
  14. To evaluate the impact of each pathway and each supportive care intervention on Intestinal Symptoms (LARS score). if indicated for the specific population
  15. To evaluate the impact of each pathway and each supportive care intervention on Anal Incontinence (Wexner score). if indicated for the specific population
  16. To evaluate the impact of each pathway and each supportive care intervention on Urinary Symptoms (USP score). if indicated for the specific population
  17. To evaluate the impact of each pathway and each supportive care intervention on Hematologic Cancer (FACT-BMT)
  18. To evaluate the impact of each pathway and each supportive care intervention on Montgomery Borgatta Caregiver Burden Scale. if indicated for the specific population.
  19. To evaluate the healthcare professionals participating in the pathway to screen vulnerability and prevent treatment related burden (F-SUS)

This is a master protocol study that is conducted by collecting sub-studies for each supportive care intervention which share key design components and operational aspects leading to a higher level of coordination than the one achieved by independently conducted studies.

Methodology: it is a mix of quantitative and qualitative methods to assess the Reach, Efficacy and potential for Adoption, while identifying barriers to Implementation and strategies to Maintain the pathway in the institution guided by the RE-AIM framework. Data collection will allow evaluation in a macro level (integrated supportive care pathway including supportive care needs assessment and tailored multidisciplinary referrals) and in a micro level (separated for each supportive care intervention).

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histological confirmation of cancer (any cancer type, any stage)
  • Age ≥ 18 years old
  • Received an integrated supportive care need assessment.
  • Sign the consent form for the PROACT study.

排除标准

  • Absence or inability of written consent from the patient.
  • Does not understand or speak French.

结局指标

主要结局

Patient distress

时间窗: over a 12-week period after the integrated supportive care needs assessment.

Patient distress collected with NCCN Distress Thermometer

Patient unmet needs

时间窗: over a 12-week period after the integrated supportive care needs assessment.

Patient unmet needs collected with problem list from NCCN Distress thermometer

次要结局

  • Impact of the pathway in Quality of life(week 12, and 24)
  • Impact of the pathway in symptom burden(week 12, and 24)
  • Impact of the pathway on insomnia levels(week 12, and 24)
  • Provider Experience - Qualitative evaluation(week 12)
  • Impact of the pathway on Functional Assessment of Cancer Therapy-Bone Marrow Transplant(week 12, week 24)
  • Reach of the pathway(week 12)
  • Diversity of pathway participants(week 12)
  • Impact of the pathway on anxiety levels(week 12, and 24)
  • Impact of the pathway on sexual health(week 12, and 24)
  • Adoption of Patient(week 12)
  • Patient Experience(week 12)
  • Maintenance of the pathway through a cost effectiveness analysis (QALYs)(week 12)
  • Impact of the pathway on caregiver burden(week 12)
  • Impact of the pathway in overall health status(week 12, and 24)
  • Adoption of Physician(week 12)
  • Patient Satisfaction/Experience - Qualitative evaluation(week 12)
  • Impact of the pathway on Urinary symptoms(week 24)
  • Patient Satisfaction with the pathway(week 12)
  • Impact of the pathway on Intestinal Symptom(week 24)
  • Impact of the pathway on healthcare professionals participating in the pathway to screen vulnerability and prevent treatment(week 12)
  • Impact of the pathway on Anal incontinence(week 24)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验